Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled, Double-blind, Multicenter, Phase IIb Study of Famitinib as Third Line Treatment in Patients With Advanced Colorectal Cancer

NCT01762293 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.

NCT NCT01762293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01762293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled, Double-blind, Multicenter, Phase IIb Study of Famitinib as Third Line Treatment in Patients With Advanced Colorectal Cancer
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2012
Completion date
October 31, 2014
Enrollment
154 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, colorectal cancer metastatic, colorectal cancer recurrent